Stockscreener 앱 받기
3.80
0.53%
0.02
시간 외 거래:
3.77
-0.03
-0.79%
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN
CRVS: Mizuho Adjusts Price Target for Corvus Pharma | CRVS Stock News - GuruFocus
Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positiv - GuruFocus
Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positive Drug Data | CRVS Stock News - GuruFocus
Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating - marketscreener.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by StockNews.com to Hold Rating - Defense World
Corvus Pharmaceuticals (CRVS) Sees Increased Investor Interest A - GuruFocus
Corvus Pharmaceuticals (CRVS) Sees Notable Increase in Borrow Ra - GuruFocus
Spotlight On Top Penny Stocks For May 2025 - simplywall.st
Corvus Pharmaceuticals’ (CRVS) Outperform Rating Reiterated at Oppenheimer - Defense World
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Call Transcript - Insider Monkey
Corvus Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS S - GuruFocus
Corvus Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS Stock News - GuruFocus
Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased - Asianet Newsable
Why Is Corvus Pharmaceuticals Stock Soaring On Friday? - Benzinga
Corvus Pharmaceuticals shares surge on positive trial results By Investing.com - Investing.com Nigeria
Corvus Pharmaceuticals shares surge on positive trial results - Investing.com
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $17 From $15, Maintains Outperform Rating - marketscreener.com
Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo
Corvus: Q1 Earnings Snapshot - New Haven Register
Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Corvus reports positive phase 1 trial results for atopic dermatitis drug - Investing.com
Corvus Pharma Reports 'Favorable' Interim Phase 1 Results in Atopic Dermatitis Trial; Shares Surge Premarket - marketscreener.com
Corvus Pharmaceuticals Inc (CRVS) Q1 2025 Earnings Call Highlights: A Turnaround with Promising ... By GuruFocus - Investing.com Canada
Corvus Pharmaceuticals Reports Promising Q1 2025 Results - TipRanks
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Corvus Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CRVS) - Seeking Alpha
Earnings call transcript: Corvus Pharmaceuticals Q1 2025 sees stock surge despite EPS miss - Investing.com India
Corvus Pharmaceuticals Reports Positive Phase 1 Trial Results - TipRanks
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of - GlobeNewswire
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Stock Titan
Post-Trade Analysis: Corvus Pharmaceuticals Inc (CRVS) Slides -6.03, Closing at 3.35 - DWinneX
Corvus Pharmaceuticals Inc (CRVS) deserves deeper analysis - uspostnews.com
CRVS Stock: More Upside For Corvus Pharmaceuticals Inc (NASDAQ: CRVS)? - Marketing Sentinel
Corvus Pharmaceuticals Inc [CRVS] Investment Appeal on the Rise - knoxdaily.com
Gaining Ground: Corvus Pharmaceuticals Inc (CRVS) Closes Lower at 3.50, Down -3.58 - DWinneX
Market Resilience: Corvus Pharmaceuticals Inc (CRVS) Finishes Strong at 3.38, Up 0.30 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
An analyst sees good growth prospects for Corvus Pharmaceuticals Inc (CRVS) - Sete News
Corvus Pharmaceuticals Inc (CRVS) deserves closer scrutiny - uspostnews.com
Upward Trajectory: Corvus Pharmaceuticals Inc (CRVS) Posts a Gaine, Closing at 3.52 - DWinneX
Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires? - EMEA Tribune
Corvus Pharmaceuticals Inc [CRVS] Investment Guide: What You Need to Know - knoxdaily.com
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 - The Manila Times
Novel Atopic Dermatitis Treatment Shows Promise: Key Phase 1 Trial Results To Be Unveiled at Major Conference - Stock Titan
0.95%
자본화:
|
볼륨(24시간):